Stocks under Review: Adobe Systems Incorporated (ADBE), Synergy Pharmaceuticals, Inc. (SGYP)


Adobe Systems Incorporated (ADBE)

Adobe Systems Incorporated is one of the largest software companies in the world. They offer a line of products and services used by creative professionals, marketers, knowledge workers, application developers, enterprises and consumers for creating, managing, delivering, measuring, optimizing and engaging with compelling content and experiences across personal computers, devices and media. They market and license their products and services directly to enterprise customers through their sales force and to end users through app stores and their own website at They offer many of their products via a Software-as-a-Service model or a managed services model as well as through term subscription and pay-per-use models. They also distribute certain products and services through a network of distributors, value-added resellers, systems integrators, independent software vendors, retailers, software developers and original equipment manufacturers.

Adobe Systems Incorporated (ADBE)‘s Financial Overview

Adobe Systems Incorporated (ADBE) declined -0.59% yesterday to close its trading session at $212.54. The company has 1 year Price Target of $248.19. Adobe Systems Incorporated has 52-Week high of $231.34 and 52-Week Low of $128.21. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 4.5 Million shares yesterday. The firm shows the market capitalization of $107.53 Billion.

The firm is trading with SMA20 of -2.57 Percent, SMA50 of SMA50 Percent and SMA200 of 23.81 percent. Adobe Systems Incorporated has P/S value of 14.73 while its P/B value stands at 12.36. Similarly, the company has Return on Assets of 11.6 percent, Return on Equity of 19.9 percent and Return on Investment of 16.7 Percent. The company shows Gross Margin and Operating Margin of 86.2 percent and 27.3 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 29 analysts offering 12-month price forecasts for Adobe Systems Inc have a median target of 220.00, with a high estimate of 253.00 and a low estimate of 165.00. The median estimate represents a +3.51% increase from the last price of 212.54.

Synergy Pharmaceuticals, Inc. (SGYP)

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.

Synergy Pharmaceuticals, Inc. (SGYP)’s Financial Outlook

The 5 analysts offering 12-month price forecasts for Synergy Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 13.00 and a low estimate of 2.35. The median estimate represents a +295.48% increase from the last price of 1.77.

According to Zacks Investment Research, Synergy Pharmaceuticals, Inc. has a Consensus Recommendation of 2.5. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock declined-1.12% and closed its last trading session at $1.77. The company has the market capitalization of $448.31 Million. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 4.73 Million shares. The company has a total of 253.28 Million shares outstanding.

The company has YTD performance of -20.63 percent. Beta for Synergy Pharmaceuticals, Inc. stands at 1.15 while its ATR (average true range) is 0.12. The company has Weekly Volatility of 5.73%% and Monthly Volatility of 6.49%.

Synergy Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -12.18%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -37%.

The Company currently has ROA (Return on Assets) of -154.3 percent, Return on Equity (ROE) of -640.9 Percent and Return on Investment (ROI) of -201.1% with Gross margin of 47.6 percent.